EXEL Exelixis Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
06:26
Aug 21
Aug 21
Exelixis approved oncology with growing EPS.
Exelixis has stable revenue, growing EPS, falling share count, approved oncology drugs for kidney, liver and thyroid cancers, and an attractive chart after breaking and retesting 50.
HIGH
About EXEL Analyst Coverage
Buzzberg tracks EXEL (Exelixis) across 1 sources. 1 bullish vs 0 bearish calls from 1 analysts. Sentiment: predominantly bullish (100%). 1 total trade idea tracked. Latest voices: Гоша.